Click Therapeutics granted FDA market authorization for digital migraine drug
Posted:
Digital therapeutic company Click Therapeutics was granted FDA marketing authorization for its prescription digital therapeutic for the preventive treatment of episodic migraines.
Healthcare innovation continues to evolve at an extraordinary pace — driven by advances in AI, digital health, virtual care, and new models of medical education.
At the centre of many of these conversations is Prof. Shafi Ahmed, our Chairman and…
Owkin and Sanofi are expanding their artificial intelligence collaboration through a multi-year agreement to co-develop AI-enabled biopharma agents for drug research and development.
Read more here.